3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
5
Withdrawn
1
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Prostatic Neoplasms
957
Urinary Bladder Neoplasms
264
Carcinoma, Renal Cell
251
Kidney Neoplasms
147
Carcinoma, Transitional Cell
129
Breast Neoplasms
127
Neoplasms
122
Colorectal Neoplasms
97
Ovarian Neoplasms
90
Melanoma
85
Carcinoma, Non-Small-Cell Lung
84
Lung Neoplasms
81
Neoplasm Metastasis
79
Pancreatic Neoplasms
68
Non-Muscle Invasive Bladder Neoplasms
68
Uterine Cervical Neoplasms
58
Stomach Neoplasms
55
Head and Neck Neoplasms
51
Squamous Cell Carcinoma of Head and Neck
47
Endometrial Neoplasms
47
Adenocarcinoma
45
Esophageal Neoplasms
44
Testicular Neoplasms
42
Carcinoma, Hepatocellular
41
Sarcoma
39
Disease
33
Triple Negative Breast Neoplasms
32
Liver Neoplasms
30
Colonic Neoplasms
29
Metastatic Castration-resistant Prostate Cancer
25
Interventions
zimberelimab
1
sacituzumab govitecan
1
pembrolizumab
1
enfortumab vedotin
1
avelumab
1
Gemcitabine
1
Cisplatin
1
Carboplatin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Metastatic Urothelial Cancer
×
Genitourinary
×
Clear all
NCT03547973
2026-03-16
TROPHY U-01
Gilead Sciences
Phase 2
Recruiting
827 enrolled
1 FDA